Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Donnelly DW, Hegarty A, Sharp L, Carsin AE, Deady S, McCluskey N, Comber H, Gavin A. The impact of adjustment for socioeconomic status on comparisons of cancer incidence between two European countries. J Cancer Epidemiol. 2013 Jan 1;2013:612514. doi: 10.1155/2013/612514
Kovac AL, Pearman MH, Khalil SN, Scuderi PE, Joslyn AF, Prillaman BA, Cox F. Ondansetron prevents postoperative emesis in male outpatients.S3A-379 study group. J Clin Anesth. 1996 Dec;8(8):644-51. doi: 10.1016/s0952-8180(96)00173-0